Introducing epiLiver: A High-throughput Test for Early Detection of Hepatocellular Carcinoma

HKG Epitherapeutics and icddr,b present epiLiver, a novel DNA methylation-based test poised to transform early detection of hepatocellular carcinoma (HCC). This innovative test offers a new hope in improving survival rates for those affected by this prevalent cancer.

Ranked as the fifth most common cancer worldwide, hepatocellular carcinoma (HCC) often remains undiagnosed until late stages, leading to low survival rates. Conventional diagnostic methods, such as imaging techniques and immunoassays using alpha-fetoprotein (AFP), exhibit limitations in early-stage detection. To address this, the team at HKG Epitherapeutics, with their background in biotechnology, and collaboration with icddr,b, a renowned clinical research institute, has developed epiLiver, a high-throughput test using DNA methylation signatures.

DNA methylation, an epigenetic mechanism controlling gene expression, exhibits a distinctive pattern in HCC samples when compared to normal tissues and blood profiles. By harnessing this unique signature, our team crafted a classifier incorporating four CpG sites—DNA segments where a cytosine nucleotide is followed by a guanine nucleotide. A particular CpG site in the F12 gene emerged as a standout, effectively distinguishing HCC samples from normal tissues, non-HCC tumors, and other blood samples. This discovery, validated in a separate dataset, marks a promising direction in HCC detection.

To turn this theory into practice, we developed a high-throughput assay using state-of-the-art next-generation sequencing and multiplexing techniques. We applied this assay to analyze plasma samples from 554 individuals, encompassing HCC patients, non-HCC cancer patients, individuals with chronic hepatitis B, and healthy controls. The results were remarkable, with a detection sensitivity of 84.5% for HCC at 95% specificity.

The development of epiLiver is part of a broader, ongoing research endeavor. Its ultimate potential will be realized when implemented amongst high-risk populations, potentially leading to a significant decrease in HCC-associated morbidity and mortality.

 Further research and technological refinements are in the pipeline, but the introduction of epiLiver represents a significant step towards more accurate, early-stage HCC detection. The test shows substantial promise as a routine early detection tool for high-risk populations, thus making a substantial contribution to collective efforts against this serious disease. The HKG Epitherapeutics team acknowledges all collaborators and participants who have contributed to this development and remains dedicated to continued work against HCC.

Please sign in or register for FREE

If you are a registered user on Research Communities by Springer Nature, please sign in

Go to the profile of Aoife Gahlawat
9 months ago

Great work, is this very specific to HCC? Have you tested other caner types`?

Go to the profile of David Cheishvili
9 months ago

Thank you for your kind words and for your interest in our work. This high-throughput test has been specifically developed for the early detection of Hepatocellular Carcinoma (HCC). To ensure its specificity to HCC, the assay underwent testing on individuals with 15 different non-HCC cancers (Fig. 5, 6 and 7 of the manuscript). 

Subscribe to the Topic

Cancer Biology
Life Sciences > Biological Sciences > Cancer Biology

Related Collections

With collections, you can get published faster and increase your visibility.

Pre-clinical drug discovery

We welcome studies reporting advances in the discovery, characterization and application of compounds active on biologically or industrially relevant targets. Examples include emerging screening technologies, the development of small bioactive compounds/peptides/proteins, and the elucidation of compound structure-activity relationships, target interactions and mechanism-of-action.

Publishing Model: Open Access

Deadline: Mar 31, 2024

Biomedical applications for nanotechnologies

Overall, there are still several challenges on the path to the clinical translation of nanomedicines, and we aim to bridge this gap by inviting submissions of articles that demonstrate the translational potential of nanomedicines with promising pre-clinical data.

Publishing Model: Open Access

Deadline: Dec 31, 2023